Innovent Biologics Inc. and Sanegene Bio USA Inc. (Sanegenebio) have announced they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension.

Axxam SpA has signed a partnership agreement with Lundbeck A/S aimed at supporting Lundbeck on early-stage drug discovery programs related to CNS indications.

Immunoscape Pte Ltd. and Mink Therapeutics Inc. have entered into a collaboration agreement to discover and develop next-generation T-cell receptor (TCR) therapies against novel targets in solid tumors.

JCR Pharmaceuticals Co. Ltd. has signed a research collaboration, option and license agreement with Alexion, Astrazeneca Rare Disease, part of Astrazeneca plc, for the development of novel oligonucleotide therapeutics with targeted delivery to certain tissues or organs using J-Brain Cargo, JCR’s proprietary blood-brain barrier-penetrating technology.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has entered into an antibody evaluation, option and license agreement with Ona Therapeutics SL.

The Novo Nordisk Foundation is committing up to DKK1.8 billion (US$260 million) to establish a research and vaccine development initiative that aims to create new or improved vaccines for respiratory diseases, including tuberculosis (TB) and influenza.

Phenomic AI Inc. has announced new collaboration agreements to help advance drug discovery for stroma-rich tumors using its Sctx single-cell transcriptomics platform.

Prism Biolab Co. Ltd. has entered into a drug discovery, license and collaboration agreement with Eli Lilly & Co.